Today: 30 April 2026
Browse Category

Health News 6 January 2026 - 24 April 2026

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s new oral weight-loss drug Foundayo was prescribed 3,707 times in its second week on the U.S. market, well below Novo Nordisk’s oral Wegovy, which saw 18,410 prescriptions in the same period after launch. Lilly shares fell about 4% following the data, while Novo Nordisk’s U.S. shares rose nearly 6%. Foundayo was approved by the FDA on April 1 and began shipping April 6.
24 April 2026
···
Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health shares rose to $26.65 Thursday after the FDA said it would reconsider restrictions on several peptides, removing 12 from a high-risk list and scheduling a July review of seven more. The move follows Hims’ March decision to stop advertising compounded GLP-1 drugs and expand branded offerings through Novo Nordisk. The company acquired a California peptide facility last year to bolster supply.
16 April 2026
···
Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly said its obesity and diabetes drug candidate retatrutide met main goals in a late-stage trial, cutting A1C by up to 2% and body weight by 16.8%. Shares traded at $918.05, down 1.3% after an HSBC downgrade and concerns over U.S. price cuts. Side effects included nausea and vomiting, with a 5.1% discontinuation rate at the highest dose. Detailed results will be presented in June.
19 March 2026
···
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said its experimental obesity drug ABBV-295 led to up to 9.79% weight loss in adults over 12 weeks in a 76-patient phase 1 trial, with no serious adverse events reported. Weekly and less-frequent dosing schedules showed similar results, while placebo groups saw little change. The study population was mostly male with a mean BMI under 30. ABBV-295 is not approved and remains in early-stage testing.
10 March 2026
····
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics shares fell 1.9% to $60.55 in premarket trading Friday after an 11.85% surge Thursday on renewed takeover speculation flagged by Betaville, The Fly reported. The company reported $116 million in 2025 Casgevy revenue and ended the year with $1.98 billion in cash. Management is set to appear at investor conferences starting March 2.
27 February 2026
···
NovoCure stock jumps in premarket after FDA clears Optune Pax for pancreatic cancer

NovoCure stock jumps in premarket after FDA clears Optune Pax for pancreatic cancer

NovoCure shares jumped 23% to $12.91 in U.S. premarket trading Thursday after the FDA approved its Optune Pax device for locally advanced pancreatic cancer. The company said this is the first new FDA-approved treatment for the disease in nearly 30 years. In a Phase 3 trial, median overall survival was 16.2 months with Optune Pax plus chemotherapy, compared to 14.2 months with chemotherapy alone.
12 February 2026
·
Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk B shares rose 5.29% to 295.50 Danish crowns Friday after Hims & Hers said it would stop selling a $49 compounded version of Novo’s Wegovy pill. The rebound followed a steep two-day drop and came as the FDA pledged action against mass-marketed copycats. The stock remains down about 20% over five sessions. Investors remain uncertain about Novo’s patent protections and future pricing power.
8 February 2026
···
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly shares rose 0.5% to $1,038.40 Friday, ahead of a holiday-shortened week. Traders are watching early U.S. prescription numbers for Novo Nordisk’s new oral Wegovy, which logged 3,071 scripts in its debut, just below Lilly’s Zepbound. U.S. markets reopen Tuesday, with investors eyeing fresh demand signals and pricing risks. About 3.8 million Lilly shares traded Friday.
19 January 2026
···
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares jumped 16.5% to $4.60 Friday after the company reported $113 million in preliminary 2025 net product revenue from ANKTIVA and disclosed accelerated approvals in Saudi Arabia for lung and bladder cancer uses. Trading volume topped 56 million shares. Enrollment in the company’s pivotal bladder-cancer trial surpassed 85%, with FDA filing planned by late 2026.
16 January 2026
···
Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recalled certain Peace by Chocolate gift boxes sold online after a supplier warned of possible Salmonella in two pistachio chocolates. The recall affects products bought on Costco.ca between Sept. 7 and Dec. 3, with no reported illnesses as of Jan. 8. Canada’s pistachio recall list now covers over 330 products. The CFIA says its investigation is ongoing and more recalls may follow.
9 January 2026
·
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk’s U.S.-listed shares rose 4.7% to $57.71 Tuesday after launching oral Wegovy for self-pay patients at $149 a month for starter doses. The pill is now available at major pharmacies and through telehealth. Investors await early demand data and updates from a key healthcare conference on Jan. 13. Rival Eli Lilly expects a regulatory decision on its own weight-loss pill in March.
6 January 2026
···
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading after the company launched an oral version of its Wegovy weight-loss drug, priced from $149 a month for some cash-paying patients. The stock traded at $57.29, up from $55.11. Investors are watching early demand and await the company’s February 4 results for margin outlook. The launch comes amid restructuring and job cuts at Novo’s U.S. operations.
6 January 2026
···
1 2 3

Stock Market Today

  • Jim Cramer's Top 10 Market Watch Items Including Hyperscalers and Eli Lilly
    April 30, 2026, 9:39 AM EDT. Jim Cramer's top 10 stock market items for Thursday April 30 spotlight hyperscalers Alphabet, Amazon, Microsoft, and Meta. Alphabet's shares surged 8% on AI spending and cloud growth. Amazon's AWS cloud expanded 28%, with shares up 3.5%. Microsoft's cloud grew 40%, but stock dipped over 1%. Meta's shares fell 8.5% after a dip in daily users and increased capital expenditures. Eli Lilly posted strong earnings, shares up 6%. Cardinal Health's quarter was weaker than expected, shares down 1%. Overall, markets look set for a positive open amid softer oil prices and yields. Federal Reserve Chair Jerome Powell plans to stay on as governor after his term ends. Anthropic is reportedly raising funds at a $900 billion valuation.

Latest article

FuelCell Energy Stock Jumps as AI Power Boom Puts FCEL Back in Play

FuelCell Energy Stock Jumps as AI Power Boom Puts FCEL Back in Play

30 April 2026
FuelCell Energy shares jumped 37% Wednesday, trading near a one-year high at $13.64 premarket Thursday, as investors bet on fuel-cell demand for AI data centers. Rival Bloom Energy reported Q1 revenue up 130% to $751.1 million and will supply up to 2.45 GW of fuel cells to Oracle’s Project Jupiter. FuelCell’s January-quarter revenue rose 61% to $30.5 million but it posted a net loss of $26.1 million.
America’s Credit Split Is Getting Worse: TransUnion Data Shows Who Is Being Squeezed

America’s Credit Split Is Getting Worse: TransUnion Data Shows Who Is Being Squeezed

30 April 2026
TransUnion reported a sharper split in U.S. consumer credit, with 15 million more borrowers in the super-prime tier since 2019, while near-prime and subprime borrowers face rising debt-to-income ratios. Bankcard balances hit $1.12 trillion in Q1, and personal loan originations reached 7.6 million in Q4, both up from a year earlier. Mortgage delinquencies of 60 days or more rose to 1.57%.
PennyMac Investor Probe Deepens After 33% Stock Plunge: What PFSI Holders Need To Know

PennyMac Investor Probe Deepens After 33% Stock Plunge: What PFSI Holders Need To Know

30 April 2026
Rosen Law Firm said it is preparing a class action for PennyMac Financial Services investors after the company’s January earnings disclosure triggered a 33.3% one-day stock drop. Schall Law Firm launched a separate investigation into possible false or misleading statements. PennyMac’s servicing segment pretax income fell to $37.3 million from $157.4 million in the prior quarter. The company reports first-quarter results May 5.
Go toTop